AWH Capital L.P. Decreases Stock Position in Evolus, Inc. $EOLS

Key Points

• AWH Capital L.P. reduced its stake in Evolus, Inc. by 5.4%, retaining 600,600 shares valued at approximately $7.23 million, making Evolus its largest position.
• Several institutional investors adjusted their positions in Evolus, with notable increases including a 988.1% increase in holdings by the State of Wyoming during the 1st quarter.
• Analysts have varied views on Evolus, with recent ratings including a hold from Needham & Company and a downgrade to sell from Wall Street Zen, reflecting mixed sentiments in the market.

AWH Capital L.P. decreased its position in shares of Evolus, Inc. (NASDAQ:EOLS - Free Report) by 5.4% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 600,600 shares of the company's stock after selling 34,400 shares during the quarter. Evolus accounts for 10.5% of AWH Capital L.P.'s portfolio, making the stock its largest position. AWH Capital L.P. owned about 0.93% of Evolus worth $7,225,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Barclays PLC grew its holdings in shares of Evolus by 12.9% during the fourth quarter. Barclays PLC now owns 105,786 shares of the company's stock valued at $1,167,000 after buying an additional 12,124 shares during the last quarter. Frontier Capital Management Co. LLC purchased a new stake in Evolus in the fourth quarter worth approximately $2,648,000. Raymond James Financial Inc. purchased a new stake in Evolus in the fourth quarter worth approximately $575,000. Comerica Bank purchased a new stake in Evolus in the fourth quarter worth approximately $312,000. Finally, Tang Capital Management LLC boosted its holdings in Evolus by 3.1% in the fourth quarter. Tang Capital Management LLC now owns 4,997,399 shares of the company's stock worth $55,171,000 after purchasing an additional 150,000 shares during the last quarter. Hedge funds and other institutional investors own 90.69% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on EOLS shares. HC Wainwright dropped their target price on shares of Evolus from $27.00 to $20.00 and set a "buy" rating on the stock in a report on Wednesday, August 6th. Wall Street Zen cut shares of Evolus from a "hold" rating to a "sell" rating in a report on Saturday, August 9th. Needham & Company LLC restated a "hold" rating and issued a $22.00 target price on shares of Evolus in a report on Wednesday, August 6th. Finally, BTIG Research dropped their target price on shares of Evolus from $21.00 to $18.00 and set a "buy" rating on the stock in a report on Wednesday, August 6th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $21.25.

Insider Buying and Selling at Evolus

In other news, insider David Moatazedi sold 111,323 shares of the firm's stock in a transaction on Friday, June 13th. The shares were sold at an average price of $10.05, for a total transaction of $1,118,796.15. Following the sale, the insider directly owned 381,509 shares in the company, valued at $3,834,165.45. This trade represents a 22.59% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Brady Stewart acquired 30,000 shares of the firm's stock in a transaction dated Friday, August 15th. The shares were purchased at an average price of $6.82 per share, for a total transaction of $204,600.00. Following the completion of the transaction, the director directly owned 88,629 shares in the company, valued at approximately $604,449.78. This trade represents a 51.17% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold a total of 133,627 shares of company stock valued at $1,325,764 over the last three months. Insiders own 5.90% of the company's stock.

Evolus Stock Performance

EOLS traded up $0.15 during trading on Friday, hitting $7.66. The company's stock had a trading volume of 534,857 shares, compared to its average volume of 1,155,379. The company has a quick ratio of 1.86, a current ratio of 2.27 and a debt-to-equity ratio of 22.00. Evolus, Inc. has a one year low of $5.71 and a one year high of $17.82. The firm has a market cap of $495.49 million, a PE ratio of -7.82 and a beta of 1.07. The business's 50 day simple moving average is $8.26 and its 200-day simple moving average is $10.19.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.